P
PLX
vs
S&P 500
S&P 500
Over the past 12 months, PLX has significantly outperformed S&P 500, delivering a return of +60% compared to S&P 500's +20% growth.
Stocks Performance
PLX vs S&P 500
Performance Gap
PLX vs S&P 500
Performance By Year
PLX vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Protalix Biotherapeutics Inc
Glance View
Protalix Biotherapeutics makes biologic medicines, especially replacement enzymes for rare genetic diseases. Its core technology grows therapeutic proteins in plant cells, not in the usual animal-cell factories, and the company turns that into finished drugs or drug candidates for rare-disease patients. Its best-known products are treatments for conditions such as Gaucher disease and Fabry disease, which are sold through partners and specialty drug channels. The company makes money mainly in two ways: it sells approved medicines and it earns income from partnerships, licensing, and development deals with larger drug companies. Those partners help fund development, manufacturing, and global marketing, while Protalix keeps a role in the underlying technology and some commercial rights. What makes Protalix different is its manufacturing platform. Instead of building a broad drug portfolio, it focuses on a small number of complex protein drugs that are hard to make with standard methods. That gives it a niche role in the rare-disease market, where the value is in the ability to produce specialized biologics reliably and to support partners that bring the drugs to patients.
